After serious adverse events were reported in patients, Gilead Sciences, Inc. has halted six clinical trials using idelalisib (Zydelig) in combination with other drugs. The trials were investigating use of the drug in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and indolent non-Hodgkin lymphomas (NHL). Leading expert Dr. Jeff Sharman joins Patient Power to explain what happened and what it could mean for patients. Watch now: patientpower.info/video/bre...
What do you think or how do you feel about this news? Did Gilead make the right call? How about Dr. Sharman's remarks?
